Experimental group:Surufatinib combined with Camrelizumab

2 trials

Sponsors

Xiangyang Central Hospital, General Hospital of Eastern Theater Command

Conditions

Biliary tumorsbiliary tract cancer

Phase 4

An exploratory study of Surufatinib combined with PD-1 antibody in second-line treatment of advanced biliary tract cancer

Active, not recruitingChiCTR2300073743

General Hospital of Eastern Theater CommandBiliary tumors

Start: 2023-07-20Updated: 2023-07-25

Unknown Phase

Single-arm, open, multicenter clinical study of Surufatinib combined with Camrelizumab in second-line treatment of patients with advanced biliary tract cancer

RecruitingChiCTR2200056017

Xiangyang Central Hospitalbiliary tract cancer

Start: 2022-09-13Updated: 2024-08-05